{
    "hands_on_practices": [
        {
            "introduction": "A frequent challenge in diagnosing peptic ulcer disease is interpreting test results in patients already receiving treatment. This practice problem simulates a common clinical dilemma where initial tests for Helicobacter pylori are negative in a child on a proton pump inhibitor (PPI). By working through this scenario , you will apply first principles of diagnostic test sensitivity and the known physiological effects of PPIs to develop a sound interpretive strategy, avoiding the pitfall of a premature or incorrect diagnosis.",
            "id": "5193632",
            "problem": "A 12-year-old child presents with 2 weeks of epigastric pain, nocturnal symptoms, and one episode of melena. There is no history of Nonsteroidal Anti-Inflammatory Drug (NSAID) use. The primary care clinician started a Proton Pump Inhibitor (PPI) 3 weeks ago (omeprazole 20 mg daily). Upper endoscopy reveals a solitary 1 cm duodenal ulcer and antral erythema. Four mucosal biopsies ($n=4$) are obtained from the antrum and corpus. Histology on hematoxylin-eosin shows chronic active gastritis characterized by neutrophilic infiltration and lymphoid aggregates, but no visible curved bacilli. The Rapid Urease Test (RUT) on antral tissue is negative. The child is otherwise healthy with mild iron-deficiency anemia. You are asked to construct an interpretive diagnostic approach to Helicobacter pylori (H. pylori) infection in this pediatric patient.\n\nUse a first-principles framework grounded in definitions of diagnostic test sensitivity and specificity, and the known effects of PPIs on gastric physiology and H. pylori biology. Specifically, reason from the following foundational bases without invoking shortcut formulas:\n- Sensitivity $Se$ is the probability $P(T+ \\mid D+)$ that a test is positive given disease is present; specificity $Sp$ is the probability $P(T- \\mid D-)$ that a test is negative given disease is absent.\n- The posterior probability of disease after a test result can be derived via Bayes’ theorem from the pre-test probability and the test’s $Se$ and $Sp$.\n- Proton Pump Inhibitors (PPIs) suppress gastric acid secretion, alter gastric pH, can reduce H. pylori bacterial load and urease activity, and can redistribute organisms to more proximal gastric sites, thereby decreasing the sensitivity of histology, RUT, stool antigen, and urea breath tests while on therapy.\n- Histology sensitivity depends on organism density, biopsy sampling strategy, and staining method; special stains (e.g., Giemsa, silver-based methods, or immunohistochemistry) increase organism detection compared with hematoxylin-eosin alone.\n- Noninvasive tests (stool antigen and ${}^{13}\\text{C}$ urea breath test) have high $Se$ and $Sp$ off PPI, but their $Se$ is reduced while on PPI; immunoglobulin G (IgG) serology is not recommended for diagnosing active infection because antibodies persist after eradication.\n\nQuestion: In light of chronic active gastritis on biopsy without visible H. pylori and a negative RUT in a child currently on PPI therapy, which of the following best represents the next step in a scientifically sound, stewardship-conscious interpretive approach to confirming or refuting H. pylori infection?\n\nA. Conclude non–H. pylori gastritis and continue long-term PPI therapy without further testing.\n\nB. Request special stains (e.g., Giemsa or immunohistochemistry) on existing gastric biopsies to increase organism detection, and if still negative, discontinue PPI for $2$ weeks and repeat testing with a high-$Se$/high-$Sp$ noninvasive assay (stool antigen or ${}^{13}\\text{C}$ urea breath test).\n\nC. Initiate empiric triple therapy for H. pylori immediately, accepting the endoscopic impression of chronic gastritis as sufficient evidence.\n\nD. Order H. pylori immunoglobulin G (IgG) serology now because it is unaffected by PPI and will reliably establish active infection.\n\nE. Schedule repeat endoscopy within $24$ hours to obtain more biopsies, because sampling error is the primary concern and timing relative to PPI use is irrelevant.",
            "solution": "Begin with core definitions. Sensitivity $Se = P(T+ \\mid D+)$ and specificity $Sp = P(T- \\mid D-)$. The negative predictive value $NPV = P(D- \\mid T-)$ depends on the pre-test probability $P(D+)$, $Se$, and $Sp$ by Bayes’ theorem. When $Se$ decreases, $NPV$ falls for a fixed pre-test probability; thus, a negative test under conditions that reduce $Se$ does not reliably exclude disease.\n\nConsider the physiology and microbiology. Proton Pump Inhibitors raise gastric pH and suppress acid secretion, altering the gastric niche. In the context of H. pylori, PPIs can:\n- Reduce organism density, lowering the chance that any given biopsy contains detectable organisms. This reduces histologic $Se$.\n- Decrease urease activity, lowering the $Se$ of RUT, stool antigen, and urea breath tests while on PPI.\n- Redistribute H. pylori proximally and patchily, increasing sampling error if biopsies are limited to distal sites.\n\nHistology on hematoxylin-eosin has lower $Se$ than with special stains because H. pylori are small, curved bacilli that can be missed without targeted staining. Giemsa, silver-based stains, or immunohistochemistry can increase $Se$ from approximately $70\\%$ with hematoxylin-eosin to $85$–$95\\%$, provided organisms are present at detectable density. However, when PPIs reduce density, even improved stains may still yield false negatives; thus, timing relative to PPI use matters for both invasive and noninvasive tests.\n\nIn this child, the pre-test probability of H. pylori is elevated by the presence of a duodenal ulcer and chronic active gastritis. Two tests (hematoxylin-eosin histology and RUT) are negative while on PPI, a condition known to reduce $Se$. Therefore, the posterior probability after negative tests is still nontrivial because $Se$ is compromised. A rational approach uses steps that:\n- Increase detection on existing samples without new invasive procedures (special stains), acknowledging patchy distribution and low density.\n- Remove the factor (PPI) that reduces $Se$ across modalities, then apply a high-$Se$ and high-$Sp$ noninvasive test (stool antigen or ${}^{13}\\text{C}$ urea breath test) after an appropriate washout (commonly 2 weeks for PPI; longer, e.g., 4 weeks, for antibiotics or bismuth).\n\nOption-by-option analysis:\n\nA. Conclude non–H. pylori gastritis and continue long-term PPI therapy without further testing.\nAnalysis: This disregards the elevated pre-test probability in a child with a duodenal ulcer and chronic active gastritis and ignores the known reduction in $Se$ of histology and RUT during PPI therapy. With reduced $Se$, $NPV$ is decreased, so a negative result does not reliably exclude H. pylori. Continuing PPI without clarifying etiology risks prolonged acid suppression and misses a treatable infection. Verdict: Incorrect.\n\nB. Request special stains (e.g., Giemsa or immunohistochemistry) on existing gastric biopsies to increase organism detection, and if still negative, discontinue PPI for $2$ weeks and repeat testing with a high-$Se$/high-$Sp$ noninvasive assay (stool antigen or ${}^{13}\\text{C}$ urea breath test).\nAnalysis: This approach first improves histologic $Se$ using special stains on already collected samples, potentially detecting organisms when hematoxylin-eosin fails. If still negative, it addresses the mechanism reducing $Se$ (PPI effect) by washout, then applies a high-performance noninvasive test off PPI. Stool antigen and ${}^{13}\\text{C}$ urea breath tests have $Se$ and $Sp$ often exceeding $90\\%$ off therapy. This sequence adheres to stewardship (avoid empiric antibiotics without confirmation), reduces unnecessary invasive procedures, and integrates test performance characteristics via Bayes’ reasoning. Verdict: Correct.\n\nC. Initiate empiric triple therapy for H. pylori immediately, accepting the endoscopic impression of chronic gastritis as sufficient evidence.\nAnalysis: Empiric antibiotics without diagnostic confirmation are discouraged in pediatrics due to antimicrobial stewardship and rising resistance. Chronic active gastritis is compatible with H. pylori but not pathognomonic; other causes exist. Given reduced $Se$ under PPI, appropriate action is to optimize detection first, not to treat empirically. Verdict: Incorrect.\n\nD. Order H. pylori immunoglobulin G (IgG) serology now because it is unaffected by PPI and will reliably establish active infection.\nAnalysis: IgG serology is indeed unaffected by PPI but cannot distinguish active from past infection. In children, serology has suboptimal $Se$ and $Sp$ for active infection and poor positive predictive value when prior exposure is possible. It does not meet the goal of confirming current infection and is not recommended for diagnosis or test-of-cure. Verdict: Incorrect.\n\nE. Schedule repeat endoscopy within $24$ hours to obtain more biopsies, because sampling error is the primary concern and timing relative to PPI use is irrelevant.\nAnalysis: Sampling error is a concern, but timing relative to PPI is highly relevant because PPI reduces organism density and detection across modalities. Repeating an invasive procedure immediately while the child is still on PPI does not correct the fundamental reduction in $Se$. Noninvasive retesting after washout is safer, cost-effective, and evidence-based; additional stains on existing biopsies are preferable before considering repeat endoscopy. Verdict: Incorrect.\n\nTherefore, the most scientifically sound, first-principles-based interpretive approach is to increase histologic detection with special stains and, if still negative, remove the suppressive factor (PPI) and retest using high-$Se$/high-$Sp$ noninvasive assays after an appropriate washout interval.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Effective management of peptic ulcer disease requires not just choosing the right medication, but also optimizing its delivery. This exercise explores how to address refractory symptoms by applying pharmacokinetic and pharmacodynamic principles to dosing strategy . You will use a simplified model to quantitatively justify why splitting the daily dose of a short-half-life drug like a proton pump inhibitor can enhance its therapeutic effect, a crucial skill for managing challenging cases.",
            "id": "5193581",
            "problem": "A $24$ kg child with endoscopically confirmed peptic ulcer disease has persistent symptoms despite standard once-daily dosing of the Proton Pump Inhibitor (PPI) omeprazole. You are asked to evaluate whether splitting the total daily dose into twice-daily administrations would improve pharmacodynamic coverage, using a simplified pharmacokinetic model grounded in first-order elimination and a concentration threshold for effective pump inhibition.\n\nAssume a one-compartment model with first-order elimination, oral bioavailability $F = 0.50$, elimination half-life $t_{1/2} = 1$ hour, and volume of distribution $V = 0.30$ L/kg. The total daily dose is set at $1$ mg/kg/day. The pharmacodynamic target is defined as maintaining plasma concentration at or above an effective threshold $C_{\\text{eff}} = 0.10$ mg/L for at least $T_{\\text{target}} = 6$ hours per day, to provide sufficient exposure during meal-stimulated parietal cell activation across morning and evening periods in a child with refractory symptoms. Assume instantaneous absorption at each administration and that exposures from separate doses do not overlap (i.e., doses are separated sufficiently).\n\nLet $N$ be the integer number of equal doses given per day, and let $D_{\\text{daily}}$ be the total daily dose. Using first principles, derive the total daily time above the effective threshold, $T(N)$, in terms of $N$, $F$, $V$, $t_{1/2}$, $C_{\\text{eff}}$, and $D_{\\text{daily}}$, and determine the minimal integer $N \\geq 1$ such that $T(N) \\geq T_{\\text{target}}$. Then compute the per-dose amount $D_{\\text{per}} = D_{\\text{daily}}/N$.\n\nReport your final answer as a two-entry row vector, where the first entry is $D_{\\text{per}}$ in milligrams and the second entry is $N$ (dimensionless). No rounding is required.",
            "solution": "The problem is first evaluated for validity.\n\n**Step 1: Extract Givens**\nThe givens extracted verbatim from the problem statement are:\n-   Child's mass: $24$ kg\n-   Pharmacokinetic model: One-compartment model with first-order elimination, instantaneous absorption.\n-   Oral bioavailability: $F = 0.50$\n-   Elimination half-life: $t_{1/2} = 1$ hour\n-   Volume of distribution (specific): $V_{\\text{specific}} = 0.30$ L/kg\n-   Total daily dose (specific): $D_{\\text{daily,specific}} = 1$ mg/kg/day\n-   Effective threshold concentration: $C_{\\text{eff}} = 0.10$ mg/L\n-   Target time above threshold: $T_{\\text{target}} = 6$ hours per day\n-   $N$: integer number of equal doses given per day\n-   $D_{\\text{daily}}$: total daily dose for the child\n-   $D_{\\text{per}}$: per-dose amount, $D_{\\text{per}} = D_{\\text{daily}}/N$\n-   Assumption: Exposures from separate doses do not overlap.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, utilizing a standard one-compartment pharmacokinetic model, which is a fundamental and widely accepted simplification used in clinical pharmacology. The parameters provided for the drug (omeprazole), such as a short half-life, bioavailability, and volume of distribution, are within realistic physiological ranges for pediatric populations. The clinical scenario—evaluating dose splitting for a drug with a short half-life to improve pharmacodynamic coverage in a patient with refractory symptoms—is a common and valid clinical question.\n\nThe problem is well-posed, objective, and self-contained. It provides all necessary information and a clear objective: to derive a general formula and then find a specific minimal integer $N$ that satisfies a given condition. The assumption of non-overlapping exposures is explicitly stated and is a reasonable simplification that makes the problem analytically tractable, especially given the short $1$-hour half-life compared to likely dosing intervals (e.g., $12$ hours for $N=2$). There are no internal contradictions, factual errors, or subjective claims.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. A complete solution will be provided.\n\n**Solution Derivation**\nThe concentration of a drug in a one-compartment model following an instantaneous oral dose is described by first-order elimination kinetics:\n$$C(t) = C_0 \\exp(-k_e t)$$\nwhere $C(t)$ is the plasma concentration at time $t$ after the dose, $C_0$ is the initial concentration at $t=0$, and $k_e$ is the first-order elimination rate constant.\n\nThe elimination rate constant $k_e$ is related to the half-life $t_{1/2}$ by:\n$$k_e = \\frac{\\ln(2)}{t_{1/2}}$$\nGiven $t_{1/2} = 1$ hr, the rate constant is $k_e = \\ln(2) \\text{ hr}^{-1}$.\n\nThe problem requires a derivation in terms of the total daily dose $D_{\\text{daily}}$ and total volume of distribution $V$. First, we compute these values for the specified child.\nThe child's mass is $m = 24$ kg.\nThe total daily dose is $D_{\\text{daily}} = D_{\\text{daily,specific}} \\times m = (1 \\text{ mg/kg}) \\times (24 \\text{ kg}) = 24$ mg.\nThe total volume of distribution is $V_{\\text{total}} = V_{\\text{specific}} \\times m = (0.30 \\text{ L/kg}) \\times (24 \\text{ kg}) = 7.2$ L.\n\nIf the total daily dose $D_{\\text{daily}}$ is divided into $N$ equal doses, the amount per dose is $D_{\\text{per}} = \\frac{D_{\\text{daily}}}{N}$.\nThe initial plasma concentration, $C_0$, immediately after one oral dose (assuming instantaneous absorption and distribution) is the bioavailable dose divided by the volume of distribution:\n$$C_0 = \\frac{F \\cdot D_{\\text{per}}}{V_{\\text{total}}} = \\frac{F \\cdot D_{\\text{daily}}}{N \\cdot V_{\\text{total}}}$$\nThe time duration for which the concentration remains at or above the effective threshold $C_{\\text{eff}}$ is found by setting $C(t) = C_{\\text{eff}}$ and solving for $t$. Let this duration be $t_{\\text{duration}}$.\n$$C_{\\text{eff}} = C_0 \\exp(-k_e t_{\\text{duration}})$$\nSolving for $t_{\\text{duration}}$:\n$$t_{\\text{duration}} = \\frac{1}{k_e} \\ln\\left(\\frac{C_0}{C_{\\text{eff}}}\\right)$$\nThis is valid only if $C_0 > C_{\\text{eff}}$. Substituting the expressions for $k_e$ and $C_0$:\n$$t_{\\text{duration}} = \\frac{t_{1/2}}{\\ln(2)} \\ln\\left(\\frac{F \\cdot D_{\\text{daily}}}{N \\cdot V_{\\text{total}} \\cdot C_{\\text{eff}}}\\right)$$\nThe total time per day that the concentration is above $C_{\\text{eff}}$, denoted by $T(N)$, is the duration from a single dose multiplied by the number of doses $N$ (given the no-overlap assumption).\n$$T(N) = N \\cdot t_{\\text{duration}} = N \\frac{t_{1/2}}{\\ln(2)} \\ln\\left(\\frac{F \\cdot D_{\\text{daily}}}{N \\cdot V_{\\text{total}} \\cdot C_{\\text{eff}}}\\right)$$\nThis is the required general expression for $T(N)$.\n\nNext, we must find the minimal integer $N \\geq 1$ such that $T(N) \\geq T_{\\text{target}}$. We substitute the given numerical values into the inequality:\n$D_{\\text{daily}} = 24$ mg, $V_{\\text{total}} = 7.2$ L, $F = 0.50$, $t_{1/2} = 1$ hr, $C_{\\text{eff}} = 0.10$ mg/L, and $T_{\\text{target}} = 6$ hr.\n\n$$N \\frac{1}{\\ln(2)} \\ln\\left(\\frac{0.50 \\cdot 24}{N \\cdot 7.2 \\cdot 0.10}\\right) \\geq 6$$\n$$N \\ln\\left(\\frac{12}{0.72 \\cdot N}\\right) \\geq 6 \\ln(2)$$\nThe term inside the logarithm simplifies: $\\frac{12}{0.72} = \\frac{1200}{72} = \\frac{100}{6} = \\frac{50}{3}$.\nThe inequality becomes:\n$$N \\ln\\left(\\frac{50}{3N}\\right) \\geq \\ln(2^6)$$\n$$N \\ln\\left(\\frac{50}{3N}\\right) \\geq \\ln(64)$$\nWe test integer values for $N$ starting from $N=1$.\n\nFor $N=1$:\nThe left-hand side is $1 \\cdot \\ln\\left(\\frac{50}{3}\\right) = \\ln(16.66...)$. Since $16.66... < 64$, we have $\\ln(16.66...) < \\ln(64)$. Thus, $N=1$ is insufficient.\n\nFor $N=2$:\nThe left-hand side is $2 \\cdot \\ln\\left(\\frac{50}{3 \\cdot 2}\\right) = 2 \\ln\\left(\\frac{25}{3}\\right) = \\ln\\left(\\left(\\frac{25}{3}\\right)^2\\right) = \\ln\\left(\\frac{625}{9}\\right) = \\ln(69.44...)$.\nSince $69.44... > 64$, we have $\\ln(69.44...) > \\ln(64)$. The condition is satisfied for $N=2$.\n\nSince the condition fails for $N=1$ and holds for $N=2$, the minimal integer number of doses per day is $N=2$.\n\nFinally, we compute the per-dose amount $D_{\\text{per}}$ for this regimen.\n$$D_{\\text{per}} = \\frac{D_{\\text{daily}}}{N} = \\frac{24 \\text{ mg}}{2} = 12 \\text{ mg}$$\n\nThe final answer consists of $D_{\\text{per}}$ and $N$.\n$D_{\\text{per}} = 12$ mg.\n$N = 2$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 12 & 2 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Managing the life-threatening complications of peptic ulcer disease, such as acute gastrointestinal hemorrhage, demands rapid and precise intervention. This hands-on problem focuses on the quantitative aspects of resuscitating a child in hypovolemic shock . By applying the principle of conservation of mass, you will calculate the effects of crystalloid and blood product administration on intravascular volume and hemoglobin concentration, reinforcing the critical link between physiological principles and emergency medical management.",
            "id": "5193597",
            "problem": "An acutely ill child with suspected peptic ulcer disease presents with large-volume hematemesis and melena. The child is hemodynamically unstable with cold extremities and prolonged capillary refill, consistent with hypovolemic shock due to upper gastrointestinal bleeding. The child’s weight is 25 kg, and the pre-bolus hemoglobin concentration is 6.8 g/dL. Use the following widely accepted physiological bases:\n- Pediatric estimated blood volume (EBV) is approximately 80 mL/kg.\n- Initial resuscitation in hypovolemia uses an isotonic crystalloid bolus of 20 mL/kg.\n- Packed red blood cells (PRBC) have a hemoglobin concentration of approximately 20 g/dL and are confined to the intravascular space over the acute time frame of resuscitation.\n- Over the short reassessment interval, isotonic crystalloid can be treated as intravascular for the purpose of hemodilution.\n- Mixing is well approximated by conservation of mass for hemoglobin, where hemoglobin mass equals concentration times intravascular volume.\n\nThe plan is to administer an isotonic crystalloid bolus of 20 mL/kg, reassess, and then transfuse PRBC only if still indicated. To inform decision-making, compute the minimal PRBC volume (in mL) that will achieve a post-transfusion hemoglobin of at least 7.2 g/dL immediately after the isotonic bolus, subject to the pediatric guideline dosing window of 10–15 mL/kg. Assume complete intravascular mixing and that intravascular volume increases by the full volumes of both crystalloid and PRBC over the relevant time frame. Round your answer to three significant figures and express it in mL.",
            "solution": "The problem statement has been critically evaluated and is determined to be valid. It is scientifically grounded in established principles of physiology and resuscitation, well-posed with a clear objective and sufficient information, and uses objective, precise language. All provided data are consistent and realistic. The solution proceeds based on the principle of conservation of mass for hemoglobin.\n\nLet $W$ be the child's weight, $H_0$ be the initial hemoglobin concentration, and $V_0$ be the initial estimated blood volume (EBV). The problem provides:\n- $W = 25 \\text{ kg}$\n- $H_0 = 6.8 \\text{ g/dL}$\n- The relationship for EBV is $80 \\text{ mL/kg}$.\n\nFirst, we calculate the child's initial blood volume, $V_0$:\n$$V_0 = 80 \\frac{\\text{mL}}{\\text{kg}} \\times W = 80 \\frac{\\text{mL}}{\\text{kg}} \\times 25 \\text{ kg} = 2000 \\text{ mL}$$\nThe total mass of hemoglobin in the circulation, $M_{Hb,0}$, is the product of its concentration and the volume. To maintain consistent units, we convert the hemoglobin concentration from $\\text{g/dL}$ to $\\text{g/mL}$, knowing that $1 \\text{ dL} = 100 \\text{ mL}$.\n$$H_0 = 6.8 \\frac{\\text{g}}{\\text{dL}} \\times \\frac{1 \\text{ dL}}{100 \\text{ mL}} = 0.068 \\frac{\\text{g}}{\\text{mL}}$$\n$$M_{Hb,0} = H_0 \\times V_0 = 0.068 \\frac{\\text{g}}{\\text{mL}} \\times 2000 \\text{ mL} = 136 \\text{ g}$$\n\nNext, an isotonic crystalloid bolus is administered. Isotonic crystalloids contain no hemoglobin. The volume of the bolus, $V_{crys}$, is given by the formula $20 \\text{ mL/kg}$.\n$$V_{crys} = 20 \\frac{\\text{mL}}{\\text{kg}} \\times W = 20 \\frac{\\text{mL}}{\\text{kg}} \\times 25 \\text{ kg} = 500 \\text{ mL}$$\nAfter this infusion, the total intravascular volume increases to $V_1$. The mass of hemoglobin remains unchanged ($M_{Hb,1} = M_{Hb,0}$), resulting in hemodilution.\n$$V_1 = V_0 + V_{crys} = 2000 \\text{ mL} + 500 \\text{ mL} = 2500 \\text{ mL}$$\nThe new hemoglobin concentration, $H_1$, is:\n$$H_1 = \\frac{M_{Hb,0}}{V_1} = \\frac{136 \\text{ g}}{2500 \\text{ mL}} = 0.0544 \\frac{\\text{g}}{\\text{mL}}$$\nIn conventional units, this is $5.44 \\text{ g/dL}$.\n\nThe next step is to transfuse packed red blood cells (PRBCs) to raise the hemoglobin concentration to a target level, $H_{final} \\ge 7.2 \\text{ g/dL}$. Let $V_{prbc}$ be the volume of PRBCs transfused. The hemoglobin concentration of the PRBCs is given as $H_{prbc} = 20 \\text{ g/dL}$.\n$$H_{prbc} = 20 \\frac{\\text{g}}{\\text{dL}} \\times \\frac{1 \\text{ dL}}{100 \\text{ mL}} = 0.20 \\frac{\\text{g}}{\\text{mL}}$$\nThe mass of hemoglobin added by the transfusion is $M_{Hb,add} = H_{prbc} \\times V_{prbc}$. The total mass of hemoglobin after transfusion, $M_{Hb,final}$, will be the sum of the hemoglobin mass after the crystalloid bolus and the added hemoglobin from the PRBCs.\n$$M_{Hb,final} = M_{Hb,1} + M_{Hb,add} = H_1 \\times V_1 + H_{prbc} \\times V_{prbc}$$\nThe final intravascular volume, $V_{final}$, is the sum of the post-crystalloid volume and the PRBC volume.\n$$V_{final} = V_1 + V_{prbc}$$\nThe final hemoglobin concentration is the ratio of the final hemoglobin mass to the final volume:\n$$H_{final} = \\frac{M_{Hb,final}}{V_{final}} = \\frac{H_1 V_1 + H_{prbc} V_{prbc}}{V_1 + V_{prbc}}$$\nWe need to find the minimal $V_{prbc}$ to achieve $H_{final} = 7.2 \\text{ g/dL}$, which is $0.072 \\text{ g/mL}$. We set $H_{final}$ to this target value and solve for $V_{prbc}$.\n$$0.072 \\frac{\\text{g}}{\\text{mL}} = \\frac{(0.0544 \\frac{\\text{g}}{\\text{mL}})(2500 \\text{ mL}) + (0.20 \\frac{\\text{g}}{\\text{mL}}) V_{prbc}}{2500 \\text{ mL} + V_{prbc}}$$\nRearranging the equation to solve for $V_{prbc}$:\n$$0.072 (2500 + V_{prbc}) = (0.0544)(2500) + 0.20 V_{prbc}$$\n$$180 + 0.072 V_{prbc} = 136 + 0.20 V_{prbc}$$\n$$180 - 136 = (0.20 - 0.072) V_{prbc}$$\n$$44 = 0.128 V_{prbc}$$\n$$V_{prbc} = \\frac{44}{0.128} \\text{ mL} = 343.75 \\text{ mL}$$\nThis is the exact volume of PRBCs required to raise the hemoglobin concentration to precisely $7.2 \\text{ g/dL}$. Since the final hemoglobin concentration is a monotonically increasing function of the transfused volume, any volume less than this will result in a hemoglobin level below the target. Therefore, this is the minimal volume required to meet the target concentration.\n\nFinally, we must verify that this volume is \"subject to the pediatric guideline dosing window of $10$–$15$ mL/kg.\"\nThe dosing window in absolute volume is:\n- Lower limit: $10 \\frac{\\text{mL}}{\\text{kg}} \\times 25 \\text{ kg} = 250 \\text{ mL}$\n- Upper limit: $15 \\frac{\\text{mL}}{\\text{kg}} \\times 25 \\text{ kg} = 375 \\text{ mL}$\nThe guideline window is $[250 \\text{ mL}, 375 \\text{ mL}]$.\nOur calculated minimal volume, $V_{prbc} = 343.75 \\text{ mL}$, falls within this valid dosing range. Thus, the minimal volume that achieves the target hemoglobin level and also complies with the dosing guideline is $343.75 \\text{ mL}$.\n\nThe problem requires the answer to be rounded to three significant figures.\n$$V_{prbc} \\approx 344 \\text{ mL}$$",
            "answer": "$$\\boxed{344}$$"
        }
    ]
}